Oncolytics Biotech (TSE:ONC) has released an update.
Oncolytics Biotech Inc. has announced a conference call to be held on March 7, 2024, to discuss its 2023 fourth quarter and full-year financial results, as well as recent operational achievements. The clinical-stage immunotherapeutics company, known for developing pelareorep—an innovative cancer treatment that modifies immune responses to target tumors, is making strides toward pivotal trials in metastatic breast and pancreatic cancers.
For further insights into TSE:ONC stock, check out TipRanks’ Stock Analysis page.
